Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / BMY - Celgene's $13.4 Billion Deal With Amgen Is a Win-Win-Win

BMY - Celgene's $13.4 Billion Deal With Amgen Is a Win-Win-Win

Bristol-Myers Squibb Company

Amgen (NASDAQ: AMGN) CEO Bob Bradway said in the big biotech's second-quarter conference call last month that Amgen was "looking at ways to grow through business development." We now know one of those ways.

On Monday morning, Amgen announced that it was buying psoriasis and psoriatic arthritis drug Otezla from Celgene (NASDAQ: CELG) for $13.4 billion in cash. This appears to be a relatively rare win-win-win kind of deal. Here are the three winners, ranked by which company I think wins the most. 

Image source: Getty Images.

Continue reading
Stock Information
Company Name: Bristol-Myers Squibb Company
Stock Symbol: BMY
Market: NYSE
Website: bms.com
Menu
BMY BMY Quote BMY Short BMY News BMY Articles BMY Message Board
Get BMY Alerts

News, Short Squeeze, Breakout and More Instantly...